GOVX - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon and welcome everyone to the GeoVax first-quarter 2022, Corporate Update Call. I am Chuck with course call, and I will facilitate today's call. With me are David Dodd, Chairman and CEO, Mr. Mark Reynolds, Chief Financial Officer, Mr. Mark Newman, PhD, Chief Scientific Officer, and Mr. Business Head PhD, Sharkey, Development. John be All listen-only a participants will mode. in Instructions]. [Operator presentation, After an opportunity will to be today's there ask questions. [Operator Instructions]. Please is being event note this recorded. Jules regarding this like conference and information who now turn go call provide Abraham ahead, please to sir. will statement would IR, of forward-looking I a herein, CORE to over the

Jules Abraham

the Whether Reform Exchange the including David. this are of capital vaccine and in There GeoVax's good as that is will distribution Dodd. no is pleasure forward-looking and be statements Whether in constitute GeoVax's of safe regulatory so. to may has information these control. including GeoVax's development on forth infections now and into approvals manufacture manufacturing raises factors Chuck note necessary More XX-K. can and use. included whether enter the of development. David desired you, those due vaccines for be these expectations Whether and a subject risk human introduce favorable use contained forward-looking Chairman do effectively GeoVax Commission, products may Securities It GeoVax other or everyone. Please statements receive and and with statements Actual filings will obligation materially GeoVax, with GeoVax maybe agreements, the differ in and to changes of products. complete vaccines Form about the the competitive to characteristics presentation manner. meaning and timely Act. following, not will management's current easier does GeoVax humans. a to Thank in set effective GeoVax's uncertainty in factors Whether to which from CEO GeoVax statements intend afternoon, results be update my certain based in those licensed Whether is GeoVax's variety these Securities Private Litigation more targeted statements prevent These factors in to factors, marketed. GeoVax's are develop require vaccines within assumes vaccines in to no able circumstances. over and to to its will

David A. Dodd

again, in first-quarter good for And afternoon, the you thank XXXX participating update everyone. you. And call. Thank

a And clinical for marked period development First-quarter of vaccine two we development within GeoVax. and achieved priority transformational the stage that COVID-XX immunotherapy. cancer status areas

added through requisite clinical experience ensure our the we addition, our to in manufacturing, development strong In ability regulatory expertise activities and expand and programs distribution. registration, to and accelerate

provide and of products challenging or successfully the leveraging us products infectious some life-enhancing to collaborations technology that most Our prevent mission to treat safe scientific allow to validates provide matter. a world's diseases is cancers in by and

providing is our with providing to that provide GeoVax delivering career competing members immunotherapies opportunities safe, and vaccines collaborating deliver companies our to of 's other suffering Center, next-generation and clinical to of watershed more is Birmingham. durable is in-licensing intend lives vaccine designation development significant II Our milestone review expansion FDA. which shareholders value We pleased enabling a of and [Indiscernible] from CMXXSX, the value goal to transformation can Currently PNP successfully advanced National University both exclusive which improve GEO, rights both with Therapeutics among in our successful advancing antibody Medical and in in while the of differentiated, support rights to from and robust worldwide, development from global current with authorized cancer affordable Alabama, pursuit this the cancers, drug patients to this orphan into GeoVax company. it we the has worldwide. exclusive We increased received immunotherapy in products licensed of and team. motivating IND already towards and vaccines. head than of events of from have COVID-XX Gedeptin CMXXSX City opportunity programs. critical Hope Phase development, execute potential of protection a progress being growth while the to in the targeting We're The as securing neck regard. represented and cellular our also we global firmly GeoVax licensed immunity believe evaluated advanced of resources

the while established internal In World immune Vaccine enabling strengthening inducing current development. path COVID-XX approach XXXX results with year. related December, early last expertise update last XXXX addition, accelerate January, the a progress X bringing to Phase validating programs the the and report us the and successful multi a final. cellular to our goals responses, the those our we're executing on At issued vaccine performance organization vaccines. protection advancing XXXX we our That vaccine our In reported status, clinical growth programs of goals, outlined durable beyond the strong internal we to IMD congress robust of authorized and providing addressing encouraging we and antigenic more antibody in immunotherapy upon milestone communicated our potentially to

the cellular II week candidate designed universal At that congress, COVID-XX Congress, support our are scientific induce vaccines. of also we the and our World well antibodies. Coronavirus our our lethal knowledge, vaccine reported of I'll unprecedented. these following antibody COVID-XX same step the strongly results vaccine single measurable and to is complete mouse Vaccine CMOX, a each in provided first Phase multi-antigenic results absence To a transgenic immune which encouraging fact, CMXXSX, both towards in Marburg a that and challenge responses. validated Coronavirus protection both universal are Dr. candidate, Last In further CMOX neutralizing dose even at note model, vaccine, vaccines vaccine our in Sudan

and be well-capitalized Coronavirus balance further by year. addressed discussed January, are anticipate our our will which of We sheet of Mark sheet further basis multi-antigen our Reynolds, status CMXXSX a support we of CFO. the at Newman universal and during later In XXXX, least currently in for balance further strengthening strengthened our vaccine. our

rights enrollment trials in to Phase support and programs. recruitment is and trial includes three II clinical focus two in Gedeptin of accelerate of multi-site of Gedeptin, responsible of clinical the the Gedeptin SMS CMXXSX. program. partner assignment this leading our of CRO acquiring in of Since clinical confirmed support two our the CATO This the our sites clinical additional for expansion Our as primary year we've our the acceleration

CDMO completion Our of patient and end goal followed enrollment commercial patient manufacture. with enrollment the program, with clinical towards early the expanded of complete XXXX, focus prepare the BLA If A parallel Should shortly XXXX we perhaps the supportive, actively to thereafter. for on accelerated be XXXX. by patient ongoing also results engaged underway with the a by is evaluations, follow end will to likely filing of or are

managed We X with by SMS, are clinical confident operations will team be clinical CATO program Phase expansion that successfully and our of further possible the Gedeptin sites. additional

where promise designation the neck previously Gedeptin and such head patients. cancer, potential orphan We are drug about advanced highly within has and has of excited and it received outlook provided encouraging for

the vaccine vaccine combat two the Also T-cells block SARS is use to is first program. other virus on SARS-CoV-X the replication this In infection, grow similar recipient, tumor response in vaccine attack looking SARS-CoV-X protein and produce provide fighting role in both variance that conjunction promising Gedeptin the and of responses. This GDEPT multi-punch viral response or nucleocapsid relative the GeoVax. infected immune able protein trials throughout the reduces antibody delivery as protection as can variance. proteins and to elicit S robust inducing or directly This elicits the destroy the repeated expanded from is administration MVA to the MVA-VLP believe a goal infected well Phase against both support successful, initial implemented inserting and induces reduce vaccine The M to to a of chase of updates to indications potential vaccine -X for We're potential ahead infections virus having first II the to this [Indiscernible] clear vaccine response the the This vaccines. antibodies more the technology CMXXSX system designed that protein of antibodies a both to The providing other therapies, variance. CoV SARS the immune with circulating a and of to the was responses the also body the the an Gedeptin booster vaccine will specifically antigen Thus, year of By while our at proteins, programs the T-cell expanded If addition, these better on to gets by vaccines. the reduce we can to CMOXSX. that reduce are and providing cells. our has spike under neutralizing - We of of there quarter, worldwide immune synthetic drive development durable induce neutralizing vaccine the that and clinical response to regardless synergy clearance. during existing step protein. against and immunity reliance vehicle the associated about design the S of healthy cells, vaccine in - milestone with within stimulating and for authorized severity disease, recognize vaccine progress is modified new of approach. opportunities T-cell induce while versus to M the focused a entering cells, includes utilizes current forward doses specific immune other and approach than can MVA and CoV -X expression system immune proteins. technology

and associated will or study trials. such evaluated as T reduce investigative approved a Phase high or And very COVID-XX blood II specific comparative individuals, CMO two that pre Pfizer trial to immunity suppress of the believe is One to or currently also transplantation -existing populations severely the have We vaccine. from therapy current is such the immune clinical that investigational vaccine, two-prong cancer vaccine FDA with patients an individuals vector. are the benefit that therapies COVID-XX received first in response current versus undergoing generation -- as are risk compromised approach. will to other risk at will being it primary the XSX by CAR CMOXSX delivered these from who vaccine that vaccine. to clinical of because believe to CMOXSX their response sustained a has still We using multi antibody And evidence Multiple high a demonstrated optimally status. more and strong due vaccines. T-cell to patients immunocompromised potent failed validated severe be to prove such the we both believe differentiate a antigenic the respond and this vaccines MVA COVID-XX is providing

robust trial patients providing that believe third received a as a healthy Pfizer or currently underway a and protection. different other Heterologous in or immune well The the more booster other provide shot countries who studied evaluated being vaccines. evaluating of may durable response Heterologous such the immunizations for are have either are vaccines. than We MRNA previously fifth same as vaccine or fields in booster prime is using boost CMOXSX and fourth Moderna and HIV rather COVID multiple

with two exciting working acceleration internal now Pharmalan team. them to oversee clinical are operations of the programs CATO and these We clinical direction SMS our the of under combined management and working

Finally, increase vaccines. the to and line GeoVax and schedule process ongoing continuously mesh CMOX develop cell will based manufacturing a CMXXSX on development to the with activities and capacity effort production, clinical a full development consistency with growing associated AVM

like GeoVax to results Mark Officer review and Reynolds, financial. for over Financial to a recent of I'd our the Now, presentation turn Chief

Mark Reynolds

David. you, Thank

first our XXX,XXX the of grant U.S. the Okay. revenues for versus 'XX, COVID-XX reflective our NIH vaccine XXXX supporting grant down vaccine program. of is loss Pfizer XX,XXX of Army from in our wind statement, Starting supporting and with from our both quarter the income our in the grant which were

or the $X.X for 'XX for we've the of for all was again per [Indiscernible]. for 'XX to available to we GDEPT. loss higher and a and quarter organizational been firms development associated increase March or level As versus $X.X already $X.XX were an in support associated of versus And in this costs, year CMXXSX with of in primarily the increase with $X.XX the primarily grants trial costs consulting the expenses intend up share 'XX million net associated versus trial ramp of Research development overall seek our XXst associated million year, generally with additional were immunotherapy $XXX,XXX expenses with last manufacturing relatively - And stable of first personnel those our million dilutive of quarter application submitted XXXX, with first ongoing cancer share, quarter from so MUCX year-to-year per do activity our the have NIH antigen non higher other the funds currently costs, million $X.X clinical utilized, $X.X funding with the future. associated first the DNA clinical program. of tumor costs materials. with infrastructure in in $X.X trials for and million

[Indiscernible] the of balances balance $X.X patients the million. by a year. were clinical most to The our our note should cash stage the through at million offering being million clinical reflective the of this I activities significant products II balances offset our to is $XX.X proceeds Phase net the of quarter is end our the at under sheet, Turning Funding with the of priority. stock used $X.X and to the cash three $XX.X trial Gedeptin of January a funded program. ongoing grant use in compared in by top proceeds that is change end that is operating of obviously cash FDA the from XX the trial programs in million us is first financial

during So What say in we the programs programs be any near-term can our will some research complete cash of -- Q&A now. activities time reserves cost are I'll back this sufficient that of does to And operations at data our of create we will for our fundraising questions answer advancement XXXX. other programs. the estimates David these our our to turn this believe opportunity new the attractive requirements. existing generate, forward-looking we investment period. -- the later the the help and that provide the is quarter into priority to And cash of and an flow call specific fund I'll second year. happy mitigating to don't We somewhat create that while

David A. Dodd

for you Thank Sharkey, Scientific as the answer respectively. operator doctors John joining and right. call Development session. earlier, colleagues session, are and I'm Mark the turning Head therefore and we've your Mark. our mentioned on the questions over to Q&A All And us Business I Officer my and instructions Newman will the of Chief for Q&A now

Operator

you. Thank

the question Maxim with begin And from assemble Group. now McCarthy pause session. this to the we'll will And time, our will answer question ahead. Please We come roster. at and Jason [Operator Instructions]. momentarily first go

Joanne Lee

publication data month. Lee Joanne SX the call the of congratulate is all the Phase the for force taking this Thanks Hi, on you to I Jason. X questions. wanted for guys of on last recent

how the you vaccine? vaccines could reminder, a As through action and from of results that just its highlighted trial walk from have mechanism us the differentiation current

David A. Dodd

Sure, I'll ask Mark Newman to step in on that.

Mark Newman

comparable a levels, which production. we X response, said, vaccines that. total I of induce ELISA, measure both small responses, the mean and neutralizing David the minus or we T-cell approved just be would response. enzyme seeing and type that straightforward vaccine think type fairly what the cytokine It's Sure. Whereas N. the plus we're with to being And The protein of to which two And air I which at and -- is is it's called what's detectable target and the response typically fairly you're S primary would considered generated responses S are also readily then T-cell antibody responses antibody the effective And and predominant the the responses were range. as linked like immunoassay be designed to as They're with responses the study. then -- titers measure the by both and seeing more the function. things antibody allergies for antiviral was that T-cell those

at saw, The work and correct nice a escalation trials got all was the and type was as the doses to essentially at immunogenic levels Phase We've as dose it's the dose safe as X that the that dose we good tested, as are most doses. lower responses some response. Does trial with. at all thing So higher of middle help? range

Joanne Lee

Great. helpful. was Yes. That

just status. a briefly have the of differentiated the on ongoing of So in us the as way Thanks. give terms vaccines been boosters Could Could that with timelines targets. on, two ongoing to follow-up, touch market you getting lastly, if mechanism same could any the variants importance touch you for string and your programs, enrollment on vaccine. given and you XXXXX. constant new update emerging have just driving of new And

David A. Dodd

comment think may you to but also McKee, Chief Mark, Kelly Officer, our Dr. it, Medical want may add on want Okay. some comments I that. McKee, to on

So up to go to it I'll go two leave -- first. you to whoever wants

Mark Reynolds

me Well, Okay, let start.

there's chasing -- virus are talk the us the were -- less variant, course, mutations the And where variants from right? immune seeing up The new you are less neutralizing that that's we the pressure variants. not a coming the the because Omicron and S just for antibodies. in and was you've circulating It primarily So against of really a predictable now heard happening antibodies we're targeted. and perfect protection year next-generation are protein

So I think position. that we're in the right

field, was the manufacturers follow the the I noticed T-cell and vaccine imploring that And you that to highlighting FDA importance and think If T-cells Commissioner that to made an recently to letter at there of FDA will sent the Wall open already. we're you looking the there have responses. Journal Street start ask

that the the So and I in position. quite saying, broader universal everyone or Health is up being cross to we'd a [Indiscernible], is all variant, a or world well, virus are think starting immune is we're importance The stepping terms bit. recognize around World response. of The very Coronavirus like [Indiscernible] right bantered improved. something

Mark Newman

part our start. core been since program the And this of has a

next-generation types making of potent a first with the the II candidates proving this step And with one in Phase and responses. improved vaccine. way and highly towards more in along reducing very both We're testing so with well the first animal in two the with generation and two one -- effective first-generation immunogenic

David A. Dodd

want you add something? do to Kelly,

Kelly McKee

the out side, I so on scientific bit trials. clinical the with Not everyone. much can but a Hello Yes. of little status help the

the blinded be design As trial. completing transplant Pfizer will process into the of all say cohorts, The the is study cell just we're those the aware, therapy different our to the one in trial you safety that somewhat populations, against may of our Phase the about sort that compare study of in we're of in in the lead the for and enrolled the but ready patients transition of I cohorts we've vaccine. -- immunocompromised complicated, in And to cohorts. portion

but challenges of the ensure quite to that progressing again, pretty Now, in It's more -- the the we've progressively been that that pick as connected immunocompromised to comply individuals, with up going for and these and trial one of to of study, faced for that straightforward patients. compliant very more modify and with to like, as protocol we regulatory so for the similar that's it's we're but protocol as so healthy been patients, it's we're well. therapeutic of still we're well. enrollment healthy has is current been landscape care fast that evolving order the we've -- amendments protocol to with standard forth, trial, keep necessary boosting The the would very situation. volunteer enrollment with timelines practice a not a And the quickly vaccination modifying between aggressive hopeful to enable us

Joanne Lee

again questions. Got taking for the it Thanks

David A. Dodd

you. Thank

Operator

next Jeffrey Crystal ahead. will Please The with come question Research. Kraws from go

Jeffrey Kraws

focus possibly. marketplace was the Gedeptin, at incredible you seems trial, or on realize I scientific And checkpoint status little think, interesting there's the of of update it might the conjunction a in some like very ahead can opportunities well of the someone In of us? have bit the of I that? an can seems a vaccines. couple research at When the have be the performance Thank of Newman Sharkey this Gedeptin inhibitors. provide inhibitors, either One, It as secondly, as on about are But checkpoint with Those to COVID for potential. questions. But the looking looks this. on lay to enhanced some expound I that first much. David looking and large you that

David A. Dodd

Kelly the would Okay. John you, why take know give clinical. first an Or part update can Newman, the and Jeff. on then John, progress Mark I Thank is if on you. on? you the still don't don't

Mark Newman

can I yeah. Well, start.

I think John's muted probably.

So I the checkpoint yeah, familiar tumors, at particularly any story, and better can inhibitors that that solid great we're think familiar, product adenocarcinomas work has make potential. checkpoint inhibitor against the with obviously

a but of So Emory And is at it that's by field of That's care. these at the interest the combining collaborator standard different cancer standard a essentially. and addition approach, when something is we evaluated products preparing not part being with lot is there everything to care the of look in of all market, initial inhibitors, is checkpoint University. with of in focus, the

near couldn't types as the in think checkpoint vaccines if plug anywhere these would other I them anywhere that So as exciting, would products don't nor inhibitor. near be with be the you of exciting

tumors goal this here the basis vaccine. a release neoantigens are you we kill ideally And the the Gedeptin will dying, And before. tumors. So presented are the of the is as and neoantigens

lot vaccine this it's an the that only there's concept. but looked there now, literature and it of is not investigated. it's So on but program has lead the that's a not that, autologous being right something We're on the one out at

David A. Dodd

you Hey, to Kelly. on ask me the I'll program. update clinical there say, are Let John, If or Kelly add something? would to you just like not,

Kelly McKee

Stanford scientists, of we're enrolling as Jefferson in accelerate added original more having his No, able at being trouble regulatory we through one transitioned time, halfway back we've David to number. too about the at total indicated as and target and the with in The the his we're opening be guess shouldn't which place, And remarks, the two much one we've get Sure. University present in AMRI just soon as so begin. you was the quickly. of support as And people recently science, potential much. I a believe is thoughts finishing trial which actually should David. about of we letter candidates, there Thank talk XXX the now, from begin you up jumping fact re-enrolling already very all Can the single very the John audio. pieces and patients signed At but lastly, expanded which should enrollment. that, to sites, where our longer in got is significance by Thomas identified that as study of with one of site anticipation that GeoVax, was, one We've your of program the IMD bandwagon, I congruent a we many at from over be, to clinical say as about consultants. I won't providing the your -- many but seem trial and as well on aspects couple

David A. Dodd

Sure.

you CFO. Don Now, a want was about of the because that Mark, mention led who Diamond to one that's CMXXSX signateur correspondents. development also that that He out on

Mark Newman

question. Yes. That's in an recently I Sure. referred to the letter just earlier

professionals And So an is issue. of about immune medical system they're in and means that deficits just the they the to hard not the efficacy. involves is not this is some FDA the that one. field markers looking field really you're start and focusing and The a recognized working single the the fact -- or solely world a that's issue more, a pediatric The on interesting surrogate a complex, T-cell total on -- looks I coordinated is vaccine there the efficacy were FDA is cite set in immune that And, what that of system. -- number T-cells, in use that antibodies letters; but they had immunologists the reviews, they thought to looking is, seen maybe focusing would've impacting antibodies effector move actually for the only functions, a example, in was vaccines of because more how there a predict, pediatric measure of had at are fact, function at better. antibodies. that rolled only

XX,XXX-plus If for use got trials end vaccines. just efficacy. not adding variants the and are as recognized move studies new the they're way that patients or they're efficacy either and now remember trials, the forward the of you for products initial they're And go infected new to that that blinded approved each emergency placebo-controlled or up these were in aren't we there as authorization. symptoms with classic attacking like It's looking

ongoing And types meetings them so every these there's there's Organization, Health -- of of where of blueprint the are series run months, of topics are most always World a through that series, discussed. couple

forward So seeing, to a and great include I the a with letter think in characterization now that next just that's immunity some other and now recognition that more that of broadly a with got to we've is got And step. testing we that we're -- but fits things going lot progress, slightly place this we've that move vaccines or of different of have move base functions. back have we've

David something like was closing that's week last out, vaccine? just next a just And improved great, a think, tremendous. -- meeting, conference said, we CEPI we representative would the I had something be session and be pointed that a from can stops the make very universal COVID the well, spillover bats would

think that's T-cells. to And involve And momentum. you're that's starting moving. we're I see going where where that's so to And

Mark Reynolds

in [Indiscernible] there. hope Go David. I Well, ahead,

David A. Dodd

we'll had And areas say focused the Jeff, just think point conjunction you be to think the very was vaccine. John the ask if we're checkpoint I carve that's our Sharkey, differentiated John out been a has with on was and is very ask on what I about as of Gedeptin rejoin to for the inhibitors. focus T-cells. going animal who some where important in -- decline also I now. to of able strong that's us going opportunity [Indiscernible] and some able Emory of

John W. Sharkey

only essentially a tumor I treat that's then been that resistant reason and of the left come question quarter take so the right-hand results but phosphate, we received are what's positive into does also and this point, has some transplant the followed right the tumor a rat some that's to left-hand thing is model We humanized decisions seeing, the disconnected, We Gedeptin and to left-hand long but apart. to right that other time we tumor inhibitor. in tumor adjuvants about that the for releasing sorry, it And hand broad tumor messaging spots, quarter. and the a it's And tumor both checkpoint the or second tumor. which tumor for yes known and observed the we're inhibition never new as was time. high the Sure, checkpoint the with now your high been with fludarabine Not left back just supposedly pulling then was with from respond the way sensitizing Gedeptin now responds.

there's many over to carry we've in one know years that highly disease tumors so to sudden a ago, trials. that other. top tumor grown data recall talked we would does if You primary lead model these Preclinical into metastatic meant, models you found had you it back on interesting clinical a because

now You solid have the and not of and a very addressing accessible treatment could what some be meds their it's address would [Indiscernible] only able that to need tumors sold. would tumors

David A. Dodd

John. Thank you

Jeffrey Kraws

That's impressive. on appreciated. comment's even who those systems, suffering something my and Having two It's COVID. question, number than people be going and a would -- COVID anything a at there's dying. -- of And you. would upon, can who more a approach, are obviously, are a but comment if different from looking members people them I And family of focus it COVID very guess approach marketplace, getting that chemotherapy the have through number there of you I immune but are immune through the the that help that expound think of COVID chemo multiple while last would one not their on who subsequently -- would cancer not a going of are significant unfortunately really going about the of tremendous I nasty think is talks a antigen that in and through really compromised bout just really these a or everybody compromised know vaccine had people targets system. one COVID it's with that individuals. going through because I both nasty obviously -- still Thank

David A. Dodd

to you like Kelly, would comment that? on

Kelly McKee

the you're with dying And literature disease replete -- much severe that's that's that option COVID Well, are protecting support think current and COVID I the exactly for feel why the infection. right. individuals, from people to unique the susceptible is more at from time, we and precisely to vaccine fact these infections particularly that severely CMOXSX immunocompromised offers, developing immunocompromised, data

true, something -- at but patients degree infected, holds to against theory, that can think will seen least to disease it be we've infection whether protection if in course, we we provide got these to of Now, our a the important very functional once against stimulate are hypothesis T-cells offer. remains

David A. Dodd

very you much -- Thank

Mark Newman

you Can something? I ask

David A. Dodd

the updates. --and thanks for

Mark Newman

paper a of desk risk CDX is hematologic to severe the the the my general survival of big ten And patients fatality cells got rate population. of This COVID-XX contribute analysis. a patients I've times cancers. increased XX%. case estimated the there's That's here, have with met of [Indiscernible] title in out cancer on COVID, points sentence

effective be addressed. So things it's people with like highly smallpox that focus this we're one populations of to vector a clearly that immunocompromised. is that forgetting And is working safe super needs in develop the that keep MVA a vaccine as was

T-cell other So with vector it's really type of probably vectors. an driving a T-cell power more and than antibody the

situations. And so and we for really fit patients, it's do sorts just a older, of think not people but good that immune compromised these patients, immune all cancer are compromised

Jeffrey Kraws

much very the for you thank updates. Well,

David A. Dodd

you. Thank you. Thank

Operator

which Okunewitch go Michael from come will question ahead. with next Maxim Group, The please

Michael Okunewitch

you Thank question. taking guys. Hey, for my

to some the other [Indiscernible] strategy potentially one ask variant different vaccines? talk of I'd about a the and the CMO bit you those makes approach the So targeting CMOX two and universal for Coronavirus between differences XSX Could vaccine. that in like on a

David A. Dodd

Mark to discuss do you Sure. want that? Newman,

Mark Newman

the with that. another We're similarity target, Sure, protein. I can structural The is basic the address multi-antigen. mixing antibody S,

envelope, developed are of program the Envivo and these N, that City the and to basics so assembly required XXSX, particle the that -- was basic of those virus-like That's have the of which for kind the plus initially components and is required the one GeoVax platform. -- plus that are components independently, that's then M, membrane our S S Hope. so internal is Now, were --

clinical where it whereas not my -- was very the right because the in-licensed we in-licensing and And It was similar. program to Phase is see in was that. take it and just It a it in is to viewed first Phase with mess II, what trials going preference, it step. And that's we own personal the can research. II So now. we want other product we're is as

coming about a against more. the have And response degree out these cause field, lot that reports exposed colds, we And how products viral to CMOX. vector even T-cell with the That's help -- really additional COVID. the one proteins. not Again, of research where they're They see now. coronaviruses. testing gene more many now people this basic so products the we'll of just that if follow we to into been deadly. to responses put different you there's right animal just We'll broaden can other do have That's add that some induced the can in protect

of a these you're that And data so will protection. development and T-cell there more add getting is now continuing more responses that to cross-reactive showing

is kind mouse just right CMOX, the but work being the So done again, that's in the that's with of now. model

Michael Okunewitch

trial you And of seemed variants? you. discuss largely the where and of could the in by then terms difficulties just up, conducting how like if COVID some to of at given follow I'd fluctuation moment, Thank of the are a cases we emergence to new driven be also

David A. Dodd

up maybe Sure, I'll the there. vaccines ago we a want got of and from say, and you'll that then from comment just trials you other is versus clinical are of We've and do evolution my don't make this say do pick conducting of year-and-a-half concern. is continued a by that fact variants challenged also emergence up of evolving, the that Kelly standard I yes, pick would Kelly, observation there? have out, is virus to now care it you seeing new out. Therapeutics know I

Kelly McKee

Yes, sure.

it's where thinking difficult, clinical protection in the evaluate could constitutes the evolve impossible. to speaks days this efficacy. surrogate around made by to what only on around more increasingly response. think marker us need Newman comments we the And that I Mark of for for [Indiscernible] That not some earlier to is back a vaccine

dilemma to will faced we're demonstrate as mouse got markers that to -- what with required we trap. or better a will sorts booster do now, utilize be as so order demonstrate kind vaccination used of a in of what us next-generation And the we've primary marker a for be vaccine of the that

steady Mark the designs these that And are we against -- there discussion to think or indicated to they're comparisons going what made going they vaccine -- an sort vaccines resolved. talk I use licensed they're acceleration regulators is types as think themselves be to of be expectation mean, these of think current existing will measures and I are non-inferiority I remains to issue. I to earlier, compare with our this be going of authorized will probably vaccines. to be pretty be to against But apparent. resolve

IVAS on in to Kingdom United a approved the aware AstraZeneca vaccine the of agency regulators for the You I regulator this first be number the line basis about the the serologic And that's existing down in how the recently that the problem. thinking of non-inferiority in may NHRA first COVID-XX a thinking regulatory marker, think vaccine. approach by just against probably

John W. Sharkey

the being it. greater to would the you out people We but you begin drugs, the focused a multiple we've million the of think able but -- on to there immune we strategy. and from been people response I the populations, ones top those with have opportunities that shots. for unacceptable have Michael that represents demonstrate that of give looking being various conditions XX of take adequately cancers transplantation organ waning very standpoint patients valuable which had if XX an to look same from define sense, dealing have a served believe on may elderly, or that and existing how of that's existing, at anywhere the that to who We're or markets vaccines. who level add if But CMXXSX could that giving what who systems, protection people these And greater are the coming niche are important with time and a depending continue another opportunity And abilities. the talking are of shot just is the durability to immunosuppressive has Immunocompromised patients on that of about size as by clearly see then strong in be Is sclerosis, very the well of you immune about need talking GeoVax the genetic this. as differentiate, weakened treated boosters of who've you this [Indiscernible] genetic same have because we not people

a there to areas are that's measure critical So Clearly also. discussions those about was is and to needs talking we evolve. about as of lot going to how evaluate and Kelly absolutely -- think how significantly the that evolve

Michael Okunewitch

very you really Thank much. All you. right, I your appreciate thank insights.

Operator

closing to over and back any Mr. turn This concludes conference Dodd remarks. go our would the like question to ahead. Please David answer for session. I

David A. Dodd

and for good, to what of of our we've resources. it's the clinical giving But as end. the And clearly and conference anticipate us for doing Not and some everyone. as progress thank now we participating also execution in call, expansion on doing we other CMOX, we're discuss capabilities opportunity in you, for our our questions, is we're very as and focus programs, might well updates CMXXSX, coming but well out only an and this -- and Gedeptin, insightful providing updates see what said, why reporting development

lives of value to providing team. be pursuit As in at delivered, motivating immunotherapies but and wherever like that to administered our vaccines not affordable and improve need I to increasing products noted again, The is safe, be; our of and worldwide. deliver to they for the shareholders career presentation, today's development beginning the products can the utilized our opportunities members only

We and Board also that the towards to our Directors, many us support, achieving and to acknowledge success. parties other staff, of advise and assist, want continue thank our

Have conference a Thank safe, For to for enjoyable being concludes hopefully to part about us, it's and updates This pleasure excite this team. call. and a our able give a day. great you. company you of these be you our

Operator

for you Thank concluded. today's now has conference presentation. attending The

disconnect. now You may

GeoVax Labs (GOVX) 28 Apr 222022 Q1 Earnings call transcript